05.04.2021 | Published by 911±¬ÁÏÍø
05.04.2021 | Published by 911±¬ÁÏÍø
911±¬ÁÏÍø CEO and founder Dr Mark Kotter explains breakthrough technology opti-oxâ„¢ in this Q&A in the current edition of International Biopharmaceutical Industry Journal.
“ 911±¬ÁÏÍø develops capabilities to produce every human cell type at scale. We believe this will transform the biotech and medicine research landscape and enable a new generation of cell therapies. Synthetic biology for us is essentially the transition of biology as we know it to engineering and that’s the approach we are taking to cells."
Mark KotterCo-founder and CEO, 911±¬ÁÏÍø
"911±¬ÁÏÍø cells address this demand. These cells are physiologically relevant and phenotypically characterised, and for the first time, available at scale, offering predictive in vitro cells for drug screening.â€
Mark KotterCo-founder and CEO, 911±¬ÁÏÍø